Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;9(1):e000700.
doi: 10.1136/lupus-2022-000700.

Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study

Affiliations

Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study

Aurelien Schlencker et al. Lupus Sci Med. 2022 May.

Abstract

Objective: Among the most significant challenges in SLE are the excessive diagnosis delay and the lack of coordinated care. The aim of the study was to investigate patient pathways in SLE in order to improve clinical and organisational challenges in the management of those with suspected and confirmed SLE.

Methods: We conducted a cross-sectional study of patients with SLE, healthcare providers and other representative stakeholders. Focus groups were conducted, and based on the collected data the most impactful disruption points in SLE patient pathways were identified. A novel framework to improve individual patient pathways in SLE was developed, discussed and validated during a consensus meeting with representative stakeholders.

Results: Six thematic clusters regarding disruption in optimal patient pathways in SLE were identified: appropriate and timely referral strategy for SLE diagnosis; the need for a dedicated consultation during which the diagnosis of SLE would be announced, and following which clarifications and psychological support offered; individualised patient pathways with coordinated care based on organ involvement, disease severity and patient preference; improved therapeutic patient education; prevention of complications such as infections, osteoporosis and cancer; and additional patient support. During the consensus meeting, the broader panel of stakeholders achieved consensus on these attributes and a framework for optimising SLE patient pathways was developed.

Conclusions: We have identified significant disruption points and developed a novel conceptual framework to improve individual patient pathways in SLE. These data may be of valuable interest to patients with SLE, their physicians, health organisations as well as policy makers.

Keywords: autoimmune diseases; patient care team; psychology; qualitative research; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

Competing interests: LA has acted as a consultant for Alexion, Amgen, AstraZeneca, Biogen, BMS, Boehringer Ingelheim, GSK, Grifols, Janssen-Cilag, LFB, Lilly, Menarini France, Medac, Novartis, Pfizer, Roche-Chugaï and UCB. Médiation Conseil Santé has been hired as a consulting agency for the organisation of the patient pathway study.

Figures

Figure 1
Figure 1
Conceptual framework for an optimised SLE pathway: (1) appropriate and timely referral strategy for SLE diagnosis; (2) dedicated consultation, during which the diagnosis of SLE is announced; (3) individualised pathways with coordinated care based on organ involvement, disease severity and patient preference; (4) improved patient education; (5) prevention and detection of complications such as infections, osteoporosis and cancer; (6) additional patient support.

References

    1. Tamirou F, Arnaud L, Talarico R, et al. . Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open 2018;4:e000793. 10.1136/rmdopen-2018-000793 - DOI - PMC - PubMed
    1. Scherlinger M, Mertz P, Sagez F, et al. . Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmun Rev 2020;19:102531. 10.1016/j.autrev.2020.102531 - DOI - PubMed
    1. Felten R, Sagez F, Gavand P-E, et al. . 10 most important contemporary challenges in the management of SLE. Lupus Sci Med 2019;6:e000303. 10.1136/lupus-2018-000303 - DOI - PMC - PubMed
    1. Piga M, Arnaud L. The main challenges in systemic lupus erythematosus: where do we stand? J Clin Med 2021;10:243. 10.3390/jcm10020243 - DOI - PMC - PubMed
    1. Cornet A, Andersen J, Myllys K, et al. . Living with systemic lupus erythematosus in 2020: a European patient survey. Lupus Sci Med 2021;8:e000469. 10.1136/lupus-2020-000469 - DOI - PMC - PubMed

Publication types